Quick Answer
BioAge Labs, Inc. reported Total Revenue of $8.99 million for fiscal year 2025.
BioAge Labs, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | $8.99M | $0.00 | — | — |
| Revenue (ASC 606) | $8.99M | $0.00 | — | — |
| Net Income | -$80.61M -13.4% |
-$71.11M -11.4% |
-$63.85M | — |
| Diluted EPS | -$2.24 +66.2% |
-$6.63 +82.6% |
-$38.17 | — |
| Total Assets | $294.89M -17.7% |
$358.23M +1281.9% |
$25.92M | — |
| Cash and Equivalents | $188.89M -46.7% |
$354.35M +1537.2% |
$21.64M | — |
| Long-Term Debt | $0.00 -100.0% |
$2.50M -69.5% |
$8.20M | — |
| Stockholders Equity | $272.05M -15.8% |
$323.13M +286.4% |
-$173.40M -54.0% |
-$112.56M |
| R&D Expense | $73.97M +25.3% |
$59.04M +74.2% |
$33.89M | — |
| Operating Income | -$92.78M -18.7% |
-$78.19M -61.6% |
-$48.40M | — |
| Shares Outstanding | 37.39M +4.3% |
35.85M +2042.5% |
1.67M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $2.05M | — | -14.8% |
| Revenue (ASC 606) | September 30, 2025 | $2.05M | — | -14.8% |
| Net Income | September 30, 2025 | -$20.17M | +13.8% | +6.5% |
| Diluted EPS | September 30, 2025 | -$0.56 | +91.6% | +6.7% |
| Total Assets | September 30, 2025 | $305.09M | -9.6% | -5.3% |
| Cash and Equivalents | September 30, 2025 | $215.57M | -35.5% | -2.2% |
| Long-Term Debt | September 30, 2025 | $0.00 | -100.0% | — |
| Stockholders Equity | September 30, 2025 | $277.46M | -11.6% | -5.9% |
| R&D Expense | September 30, 2025 | $18.51M | -7.5% | -6.7% |
| Operating Income | September 30, 2025 | -$23.14M | +6.5% | +6.6% |
| Shares Outstanding | September 30, 2025 | 35.85M | +4.8% | +0.0% |
- BioAge Labs, Inc. reported Total Revenue of $8.99 million for fiscal year 2025.
- BioAge Labs, Inc. reported Revenue (ASC 606) of $8.99 million for fiscal year 2025.
- BioAge Labs, Inc. reported Net Income of -$80.61 million for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -13.4% in Net Income compared to the prior fiscal year.
- BioAge Labs, Inc. reported Diluted EPS of $2.24 per share (loss) for fiscal year 2025.
- BioAge Labs, Inc. showed an increase of +66.2% in Diluted EPS compared to the prior fiscal year.
- BioAge Labs, Inc. reported Total Assets of $294.89 million for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -17.7% in Total Assets compared to the prior fiscal year.
- BioAge Labs, Inc. reported Cash and Equivalents of $188.89 million for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -46.7% in Cash and Equivalents compared to the prior fiscal year.
- BioAge Labs, Inc. reported Long-Term Debt of $0.00 for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- BioAge Labs, Inc. reported Stockholders Equity of $272.05 million for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -15.8% in Stockholders Equity compared to the prior fiscal year.
- BioAge Labs, Inc. reported R&D Expense of $73.97 million for fiscal year 2025.
- BioAge Labs, Inc. showed an increase of +25.3% in R&D Expense compared to the prior fiscal year.
- BioAge Labs, Inc. reported Operating Income of -$92.78 million for fiscal year 2025.
- BioAge Labs, Inc. showed a decrease of -18.7% in Operating Income compared to the prior fiscal year.
- BioAge Labs, Inc. reported Shares Outstanding of 37.39 million shares for fiscal year 2025.
- BioAge Labs, Inc. showed an increase of +4.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: